Patents by Inventor William C. Mobley
William C. Mobley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210386981Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Applicant: NEUROFLUIDICS, INC.Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
-
Publication number: 20210386982Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Applicant: NEUROFLUIDICS, INC.Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
-
Patent number: 11117884Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.Type: GrantFiled: October 25, 2019Date of Patent: September 14, 2021Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 11065425Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: GrantFiled: August 22, 2019Date of Patent: July 20, 2021Assignee: Neurofluidics, Inc.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Patent number: 11040179Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: GrantFiled: August 22, 2019Date of Patent: June 22, 2021Assignee: Neurofluidics, Inc.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Publication number: 20200055840Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.Type: ApplicationFiled: October 25, 2019Publication date: February 20, 2020Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Publication number: 20200046954Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: ApplicationFiled: August 22, 2019Publication date: February 13, 2020Applicant: NEUROFLUIDICS, INC.Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
-
Patent number: 10472346Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.Type: GrantFiled: October 30, 2015Date of Patent: November 12, 2019Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 10398884Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: GrantFiled: January 19, 2017Date of Patent: September 3, 2019Assignee: NEUROFLUIDICS, INC.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Patent number: 9938263Abstract: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.Type: GrantFiled: March 12, 2014Date of Patent: April 10, 2018Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Rudolph E. Tanzi, Steven L. Wagner, Soan Cheng, William C. Mobley
-
Publication number: 20180093967Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.Type: ApplicationFiled: October 30, 2015Publication date: April 5, 2018Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
-
Patent number: 9895518Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: GrantFiled: March 13, 2013Date of Patent: February 20, 2018Assignee: NEUROFLUIDICS, INC.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Publication number: 20170203084Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: ApplicationFiled: January 19, 2017Publication date: July 20, 2017Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Patent number: 9403815Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.Type: GrantFiled: June 24, 2011Date of Patent: August 2, 2016Assignees: The Regents of the University of California, The General Hospital CorporationInventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
-
Publication number: 20160024073Abstract: There are provided, imer alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Inventors: Rudolph E. TANZI, Steven L. WAGNER, Soan CHENG, William C. MOBLEY
-
Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
Patent number: 9072730Abstract: A method of treating an individual having Down syndrome or Alzheimer's disease, which entails the step of administering an amount of one or more compounds to the individual which improve cognitive functioning in the individual by increasing hippocampal NE levels.Type: GrantFiled: May 14, 2010Date of Patent: July 7, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ahmad Salehi, William C. Mobley, Janice Vallette -
Publication number: 20140066830Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: ApplicationFiled: March 13, 2013Publication date: March 6, 2014Applicant: Neurofluidics, Inc.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Publication number: 20130165416Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.Type: ApplicationFiled: June 24, 2011Publication date: June 27, 2013Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
-
Patent number: 8435204Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. A multilumen flow path allows exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.Type: GrantFiled: October 9, 2007Date of Patent: May 7, 2013Assignee: Neurofluidics, Inc.Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
-
Publication number: 20120225848Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.Type: ApplicationFiled: September 17, 2010Publication date: September 6, 2012Inventors: Alexander M. Kleschevnikov, William C. Mobley